AMGen (Applied Molecular Genetics Inc.) established as a California corporation on April 8
George B. Rathmann named CEO
1983
Company changes name to Amgen
A research team led by Fu-Kuen Lin clones the gene for human erythropoietin (EPO) and produces recombinant EPO, later patented and named EPOGEN® (Epoetin alfa)
Initial Public Offering of 2,350,000 shares at $18 per share raises $40 million
1985
A research team led by Larry M. Souza clones the gene for human granulocyte colony-stimulating factor (G-CSF) and produces recombinant G-CSF, later patented and named NEUPOGEN®
1987
Amgen receives first patent on DNA used in producing Epoetin alfa
1988
Gordon M. Binder named CEO
1989
Immunex clones the gene for a soluble TNF receptor and later develops and patents a fusion product, Enbrel® (etanercept)
Amgen receives first U.S. patent for recombinant G-CSF (NEUPOGEN®)
FDA approves EPOGEN® for the treatment of anemia in patients with end-stage renal disease
EPOGEN® named "Product of the Year" by Fortune magazine
1991
FDA approves NEUPOGEN® to decrease the incidence of infection associated with chemotherapy-induced neutropenia in patients with non-myeloid cancers
Amgen establishes the Amgen Foundation for charitable giving
NEUPOGEN® named "Product of the Year" by Fortune magazine
Federal Appeals Court rules in Amgen’s favor in EPO patent dispute with Genetic Institute
1992
Amgen sales surpass $1 billion
1994
Amgen receives U.S. Department of Commerce National Medal of Technology
1996
Amgen sales surpass $2 billion
1998
FDA approves Enbrel® (etanercept) to treat patients with rheumatoid arthritis
1999
Amgen sales surpass $3 billion
FDA approves Enbrel® to treat moderately to severely active polyarticular-course juvenile rheumatoid arthritis
2000
Kevin W. Sharer named CEO
2001
FDA approves Aranesp® (darbepoetin alfa) to treat anemia associated with chronic renal failure
2002
FDA and EMEA approve Neulasta® (pegfilgrastim) to decrease the incidence of infection in patients with non-myeloid cancers receiving chemotherapy
FDA approves Aranesp® for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies
Amgen completes Immunex acquisition
FDA approves Amgen’s Rhode Island manufacturing facility for ENBREL
FDA approves Enbrel® to treat the signs and symptoms of active arthritis in patients with psoriatic arthritis
2003
FDA approves Enbrel® for the treatment of ankylosing spondylitis and other expanded indications
2004
The FDA and EMEA approve respectively Sensipar® and Mimpara® (cinacalcet HCl) for the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis
FDA approves Enbrel® for the treatment of chronic moderate to severe plaque psoriasis in adults
Amgen completes Tularik acquisition
FDA approves Kepivance™ (palifermin) to decrease the incidence and duration of severe oral mucositis in patients with hematologic cancers undergoing high-dose chemotherapy and bone marrow transplant.
2005
EMEA approves Kepivance® , Aranesp® Sureclick™ and Neulasta®Sureclick™
Amgen Europe BV (Breda) receives Gazellen award for fastest growing company in the
province Brabant.
